EA3191

1. 01

   A potentially less-toxic replacement is the hope—not an established advantage

2. 02

   Resectability and patient goals separate the curative discussion from systemic treatment and response-dependent deferral

3. 03

   Symptom burden makes control-arm composition consequential in the connected discussion of alternative trials

4. 04

   Brachial plexus protection is described as a cumulative-dose, interval and counseling problem

   Sample finding · free

   A speaker in an X thread asked how to reduce brachial plexus injury during repeat radiation when treatment fields overlap.

   Source: X thread, 2025-08-16 · paraphrased; the full report links the source

5. 05

   Reirradiation questions extend from diagnosis and intent to dose, field size and acceptable harm

6. 06

   Cumulative-dose calculations and recovery assumptions are viewed as uncertain and operationally fragile

   Sample finding · free

   Speakers in an X thread asked whether recovery estimates should address organs other than the spinal cord and whether quality assurance should be part of reirradiation.

   Source: X thread · paraphrased; the full report links the source

7. 07

   Multidisciplinary support is part of treatment feasibility, including during palliative systemic therapy

8. 08

   Access, consent and accrual are practical conditions for answering the research question

The full report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified claims with exact source passages.

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

2023-04-25 → 2026-10-01

Cited window

2023-04-25 → 2026-10-01

Retrieved

2026-10-07

Title

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features

Registry

NCT04671667

Study IDs

NCI-2020-13174 · EA3191 (ECOG-ACRIN Cancer Research Group) · EA3191 (CTEP) · U10CA180820

Sponsor

National Cancer Institute (NCI)

Design

Phase 2 · interventional, randomized, parallel, phase2

Status

Recruiting

Enrollment

188 estimated

Start

2021-04-27 actual

Primary completion

2029-06-30 estimated

Primary endpoint

Overall survival (OS)

Interventions

7 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
• –2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
• –8 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
• –The reviewed discussion is not representative of all HCP views. Searches centered on identifiers and aliases may have missed unnamed references or different transcription variants.
• –Related panel recordings and repeated organizational posts are not independent endorsements and should not be used to estimate consensus.
• –The unidentified video respondent cannot be named from the supplied source. A named podcast passage does not establish ownership of the video remarks.
• –Some connected discussion is not fully represented: treatment-selection rationale in the case recap, timing of multidisciplinary re-engagement, dose-recovery guidance and its qualifications, renal-function-dependent systemic alternatives, alternative-agent durability and HPV-related evidence limits, and biomarker-based selection among bispecifics. These omissions limit the completeness of the reported decision rationales.
• –No exact-trial publication, comparative readout or full protocol document was available. Reported regimen, eligibility and dose-limit details remain attached to the speakers who described them.
• –Post and publication dates are not confirmed session dates. Local availability, enrollment and renovation accounts describe their presentation setting, not assured current access.
• –Broader reirradiation opinions include other treatment intents and disease sites; they do not establish EA3191-specific dose, target-volume or technique recommendations.
• –Some presenters have limited separate professional context. Their source-established identities do not justify assuming additional clinical credentials or giving their claims greater evidentiary weight.
• –The patient-facing video's rendered clinicaltrials.gov link contains NCT05533558 rather than the target NCT04671667; it is retained as transcribed, not endorsed as a verified referral link.

How reports are built and checked: Methods.

Last checked Oct 7, 2026. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch. No corrections.

release b2013786f75a6b2db43ddfd6228ddc5fad068187a3c2fa93903adaecf4e863ef

The same record as JSON or Markdown, or through the Erudio MCP server.

curl https://www.erudio.com/reports/ea3191-nct04671667.json
curl https://www.erudio.com/reports/ea3191-nct04671667.md

# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "ea3191-04671667" })